Annual General Meeting Presentation
Released
Released
Announcement PDF
AGM presentation
November 2020
Michael Winlo - MD & CEO
ASX:EMD
DRAFT
Disclaimer and notices
This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or
investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction.
This presentation contains general information only and does not consider the investment objectives, financial situation and needs of individual
investors. Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice
from a qualified financial adviser having regard to their personal objectives, financial situation and needs before taking any action. No
representation or warranty, express or implied, is made as to the accuracy, completeness, reliability or adequacy of any statements, estimates,
opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation
or warranty (express or implied) given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective
statements or returns contained in this presentation. Such forecasts, prospective statements or returns are by their nature subject to significant
uncertainties and contingencies, many of which are outside the control of Emyria. To the maximum extent permitted by law, Emyria and its related
bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including without limitation any liability
arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything
contained in, or omitted from, this presentation. An investment in Emyria securities should be considered speculative and is subject to investment
and other known and unknown risks, some of which are beyond the control of Emyria. Emyria does not guarantee any rate of return or the absolute
or relative investment performance of Emyria securities. The distribution of this presentation including in jurisdictions outside Australia, may be
restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions.
This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of
operations and business of Emyria and certain of the plans and objectives of Emyria with respect to these items. These forward-looking statements
are not historical facts but rather are based on Emyria's current expectations, estimates and projections about the industry in which Emyria
operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and
similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject
to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of
building a business around such products and services. These statements are not guarantees of future performance and are subject to known and
unknown risks, uncertainties and other factors, some of which are beyond the control of Emyria, are difficult to predict and could cause actual
results to differ materially from those expressed or forecasted in the forward looking statements. Emyria cautions shareholders and prospective
shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Emyria only as of the date of this release.
The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Emyria will not
undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or
unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
Presentation release authorised by Michael Winlo, CEO and Managing Director
Funding
history
& milestones
in6first
9 months
Funding
history
& milestones
in first
months
History
Milestones
•
Listed on the ASX, 12 February 2020 (ticker: EMD)
•
$1m+ total contract value of data deals
•
Last reported cash position (Q3, 2020): $4.2m
•
Unique insights a source of IP for Emyria
•
3,000+ patients referred to Emerald Clinics
•
+ $954,000 R&D refund (02 Nov 2020)
•
Market cap: $16.7m (12 Nov 20)
•
UK partnership (Sapphire Medical)
•
Shares on issue 211.4m
•
Developing unique technology IP
•
Options on issue 18.3m (strike $0.45)
•
Class 1 TGA registration for Openly
•
Strategic partnership with Mt Sinai
Experienced board with drug development and tech focus
Key Person
Role
Previous Experience
Chairman & Founder
Cynata (ASX:CYP) – stem cells
Orthocell (ASX:OCC) – regenerative medicine
Botanix (ASX:BOT) – CBD (synthetic) for topical and antimicrobial use
AusCann (ASX:AC8) – hard capsule cannabinoid medicines
Zelira (ASX:ZLD) – cannabinoid clinical development
Managing Director
Medical doctor
Complex data analysis (Palantir - a Peter Thiel founded company based in Silicon Valley)
Director and ex-CEO at Linear Clinical Research
MBA from Stanford University Graduate School of Business
Dr Alistair Vickery
Chief Medical
Officer & Director
Specialist general practitioner with >30 years’ experience
Associate Professor of Primary Health Care at University of Western Australia
Deputy Chair of the Postgraduate Medical Council of WA
Chair of Black Swan Health, one of the largest primary health care service
Matt Callahan
Non-Executive
Director & Founder
Founder of Botanix Pharmaceuticals (ASX:BOT), iCeutica Inc. and Orthocell (ASX:OCC)
Successfully developed 4 products through FDA approval.
More than 20 years’ legal, intellectual property and investment management experience
Professor Sir John
Tooke
Independent NonExecutive Director
Senior Independent Director, BUPA Chile
Chair of Collaboration for the Advancement of Sustainable Medical Innovation (CASMI), UCL
Sir Tooke was Head of the School of Life and Medical Sciences at University College London (UCL)
Immediate past President of the Academy of Medical Sciences in the
Previous member of Google DeepMind Health’s Independent Review Board.
Leading advisor to the UK Government regarding health policy
Knighted in the United Kingdom in the 2007 New Year Honours for Services to Medicine.
Dr Stewart Washer
Dr Michael Winlo
Traditional drug development
Product registration
Product monitoring
Initial drug
registration
Discovery
Preclinical
Studies
Preclinical
studies
Phase 1, 2, 3 clinical trials
Post registration monitoring
what is the drug?
how might it work?
is it safe?
does it work?
what is the target disease?
is it still safe?
does it work for anything else?
is it cost effective?
10-20 years
Sources:
|
~$2.6 billion
|
Potential
indication
expansion
95% failure rate
Agres T. New Life for Old Drugs. Drug Discovery and Development. July 29, 2011. Accessible at: http://www. dddmag.com/articles/2011/07/new-life-old-drugs
Mullin R. Tufts Study Finds Big Rise in Cost of Drug Development. Nov. 20, 2014. Accessible at: http://cen.acs.org/ articles/92/web/2014/11/Tufts-Study-Finds-Big-Rise.html
Real world evidence (RWE) accelerates drug registration
Product registration
Product monitoring
Initial drug
registration
Discovery
Preclinical
Studies
Preclinical
studies
what is the drug?
how might it work?
Emyria
Post registration monitoring
Trials + real-world data
is it safe?
does it work?
what is the target disease?
Care
Provides:
• Access to patients with unmet needs
• Safe provision of new treatments by
experienced care team
• Continuous safety and efficacy monitoring
Potential
indication
expansion
is it still safe?
does it work for anything else?
is it cost effective?
Emyria
Data
Provides:
• Rapid indication insights leading to faster drug registration
• Strategic trial design using real-world patient data
• Support for payment coverage decisions
• Discovery of novel therapies
RWE saves time and costs in drug registration
Product registration
Product monitoring
Initial drug
registration
Discovery
Preclinical
Studies
Preclinical
studies
what is the drug?
how might it work?
Trials + real-world data
is it safe?
does it work?
what is the target disease?
Potential
indication
expansion
Post registration monitoring
is it still safe?
does it work for anything else?
is it cost effective?
RWE can save between $100m and $1b per drug
Sources:
Hughs B. Kessler M. McDonnel A. Breaking New Ground with RWE Accessible at: https://www.iqvia.com/-/media/quintilesims/pdfs/qims_breaking_new_ground_with_rwe_whitepaper.pdf
Why registration matters
Special Access Scheme (eg. all cannabinoid medicines in Aus)
Consultation with
doctor
Submit notification
application
+
supporting evidence
Check State /
Territory
requirements
Is stock available?
Consent to
treatment with
unregistered
medicine
Collect prescription
Patient pays out of
pocket
Registered medicines
Consultation with
doctor
Collect prescription
PBS may pay
Sources:
https://www.tga.gov.au/form/special-access-scheme
Registered medicines provide:
Greater patient access
Faster access for patients
Lower out-of-pocket patient costs
How Emyria accelerates drug registration
Emyria
Patients
with unmet
medical
needs
Care
Novel
treatments
Emyria
Data
Regulator-grade data:
• Validated clinical endpoints
• Patient-reported outcomes
• Precise dosing data
• Patient stratification
• Safety + adverse event
monitoring
Drug registration
Emyria data helps answer:
• What dose is most effective?
• Which patient sub-groups
benefit most?
• What are the key adverse
events and
contraindications?
• And more…
Emyria’s Digital Health Platform
Emyria provides care for patients with unmet medical
needs. Collectively, this patient group represents a
large proportion of health costs and a group
motivated to access new care models and treatments.
Emyria’s data platform generates unique and valuable
data. Emyria data can be used as clinical evidence to
help answer what treatments are working, for whom
and at what dose to support formal drug registration.
Emyria successes to date
Emyria
Care
Emyria
Data
Drug registration
• Over 3,000 referrals
• Over 2.5M data points
• Multiple global clients
• Over 54 medical needs
• Over $1M data deals
• Multiple unmet needs
• Australia + UK
• Unique IP captured
• Growing therapy base
Emyria’s Digital Health Platform
• TGA registration as a medical device
• Partnership with Mt Sinai
• Unique, contactless vital sign technology integrated
Creates
Emyria
Care
Accelerates
Emyria
Data
Emyria data
Emyria care
Informs
Drug registration
informs
Emyria elevates care for patients
with unmet medical needs
DRAFT
Emyria
Care
We support unmet needs with high cost burden
Core unmet need
(% of Emyria patients)
Chronic pain
(~60%)
Neurological
disorders
(~10%)
Mental health
(~60%)
Size of patient
Australian health system
population in Australia
costs
3.37 million
0.2 million
4.8 million
$12.64 billion
$31 billion
$60 billion
Notes
References
44.6% of patients living with
chronic pain also experience
depression or anxiety
https://
www.painaustralia.org.au/
about-pain/painful-facts
Cost of this health burden
grew 15.6% between 2011-17
https://www.neura.edu.au/
news/new-report-reveals-theaustralian-burden-of-diseasefor-brain-disorders-is-almosttwice-the-global-figure
COVID-19 has dramatically
increased demand for mental
health support services
https://www.aph.gov.au/
About_Parliament/
Parliamentary_Departments/
Parliamentary_Library/pubs/rp/
rp1819/Quick_Guides/
MentalHealth
Emyria
Care
We train and develop clinical experts
Dr Alistair
Vickery
Dr Jennifer
Morgan
Dr Nelson Lau
Dr Jennifer Tai
Pictured: Some of Emyria’s clinical team.
For more details on our care team, please visit www.emyria.com
Dr Phil Finch
Dr David Gunn
Dr Ben Addison
Emyria
Care
We specialise in novel & unregistered treatments
Revenues
Treatment
pipeline
Cannabinoids
Product
selection
QA
checks
Clinical
service
design
Patient
care
Data
deals
AUS (Emerald Clinics)
UK (Sapphire Clinics)
Psychedelics *
Others
Active
In planning
* Under Australia’s Therapeutic Goods Administration (TGA), psychedelic medications such as psilocybin and MDMA are currently Schedule 9 of the Uniform Scheduling of Medicines and Poisons (which deals with Prohibited Substances).
They are only available via approved research trials that include oversight by an institutional research ethics committee and careful monitoring and reporting of efficacy and safety outcomes. There is an active rescheduling proposal
before TGA so that they can be more easily used as clinical therapies for the treatment of mental illnesses. The rescheduling would move these medicines to Schedule 8 (which deals with Controlled Medicines), the same category as THCcontaining cannabinoid medicines. For more information : https://www.tga.gov.au/consultation-invitation/consultation-proposed-amendments-poisons-standard-acms-accs-and-joint-acmsaccs-meetings-november-2020
Case Study - Bob
•
Vietnam Veteran | injured by fall in 1969 | multiple fractures
•
Chronic back pain | peripheral neuropathy from Agent Orange | PTSD
•
At initial visit: oxycontin | buprenorphine | pregabalin | gabapentin | PEA
duloxetine – with little relief and side effects.
•
Now: Stable at 15mg 1:1 THC/CBD | ceased all opiates, pregabalin and PEA
Scores
Initial assessment
Visit 5
BPI Pain severity score
5.0
1.75
BPI Pain interference score
5.29
0.86
Visual analogue scale
5.0
1.0
Insomnia severity score
12.0
1.0
DASS 42 Depression
14
4
DASS 42 Anxiety
16
2
DASS 42 Stress
16
12
Emyria
Care
Growth story so far
Enter UK partnership with
Sapphire Medical - first
accredited medicinal
cannabis clinic in the UK.
Opened a specialist clinic for
mental health and substance
abuse in Northern NSW
Clinic locations across Australia
- Perth, Melbourne, Sydney
Feb
Care
Mar
2,000+
patients
Apr
Care
May
Jun
Care
Jul
Aug
3,000+
patients
Care
Sep
Oct
Care
Nov
Further growth in
clinical services and
into new treatment
areas
Next
Emyria
Data
indication-specific dose
response insights
Insights + services to
help developers obtain a
drug registration (i.e. a
strategic trial design
clinical trial execution
“label claim”)
registration and
repurposing submission
support
Emyria
Data
Revenues from data & registration milestones
Data insights
revenue
Unmet medical needs
Collect
data
Patient
Productstratification specific insights
Clinical
trials
Registration Monitoring
Insomnia
Chronic non-cancer pain
Autism
Mental Health (PTSD, depression)
Chemotherapy symptoms
Irritable Bowel Syndrome
Cancer Pain
Neurological Spasticity
Parkinson's Disease
Completed
In progress/
planning
Migraine (headache)
Epilepsy
Alzheimer's Disease
Anorexia & wasting chronic illness
Dementia
Inflammatory Bowel Disease
Others
Emyria’s diverse patient population
and data supports multiple drug
registration programs that can be
pursued with partners or
independently
Case Study - Spectrum
•
Emyria approached in 2019 to develop a pharmacovigilance product registry
for largest cannabis company in the world
•
To include safety data for Australian patients taking Spectrum products seen
through Emerald Clinics.
•
Total contract values
over $1M (AUD)
After just 6 months, Emyria’s PV services were expanded to include UK
drug monitoring
paid activities
Location
Australia
Medicinal Cannabis arm of
Canopy Growth, Largest
cannabis company in the
world with market
capitalisation = $6.94B USD
(Oct 7, 20)
UK
For more details, please see ASX announcement dated 10 AUG 2020
Development
Quality assurance
Case Study - Zelira
•
Emyria approached in 2019 and provided insomnia-related outcome insights from Emyria’s real-world data. These
insights supported a Phase 2 trial.
•
In parallel, Emyria conducted a home-based Phase 1 clinical trial via our national network - Emerald Clinics
•
Emyria is now supporting registration strategies with insights and trial support for multiple indications in areas of
major unmet need.
product registration paid activities
Indications
A global medicinal
cannabis company
pursuing multiple, large
clinical indications =
Market capitalisation
$87M (Oct 7, 20)
Data insights
Proof-of-concept
trials
Opioid
Sparing
Insomnia
Autism
For more details, please see ASX announcements dated 27 FEB 2020, 30 SEP 2020 and 09 NOV 2020
Late phase trials
Registration
submissions
Emyria
Phase 1 trial
(Opioids)
Feb
Data
Care
Growth story so far
Product registry
(UK)
Product registry
(AUS)
Care
Mar
Apr
Care
May
Jun
Care
Jul
Aug
Trial
(Insomnia)
Trial
(Autism)
Care
Sep
Oct
More data deals,
unique IP to
support new
product
development
Care
Nov
Next
Emyria’s
digital health
Emyria is investing in the
future of care
patient-centric care
in the home
improve clinical efficiency
and evidence capture
helps clinical team stay
connected to patients
supports delivery of datadriven care plans
Case Study - Openly
Health screening, powered
by your smartphone and
backed by a clinical team
• Mobile app captures clinical vital signs using just a Smartphone - eg
heart rate & heart rate variability - important signs of physiological
stress (eg early signs of infection or mental health changes)
• App also captures patient reported outcomes
• Partnership with Mt Sinai, largest hospital network in New York
• TGA registration as a “Class 1 medical device” (ARTG ID 343533)
Emyria’s digital
health platform
Simple, Scalable
Screening in Seconds
Actionable Insights
Mobile-based supports large
populations
Easy to use screenings and
objective clinical measurements
Aggregates population health
data to manage risks
Emyria’s digital health technology
improves value of data
Emyria positioned to rapidly bring new treatments to patients
Emyria
Care
Emyria
Data
• Partnership growth
• Continued growth of
patient base
• Additional service
Drug registration
• Unique IP to support
• New therapeutic areas
new products
• Focus on high unmet
• Additional partnerships
needs (chronic disease
offerings
and mental health)
Emyria’s Digital Health Platform
• Additional TGA registrations as a medical device
• Develop technology partnerships to support strategy
• Use unique contactless vital sign technology to develop digital biomarkers
Contact Information
Michael Winlo: mwinlo@emyria.com
Investors: investors@emyria.com
Media: media@emyria.com
General: info@emyria.com
ASX:EMD
DRAFT
Share your feedback
Discover